IMMUNOCORE HOLDINGS LTD
NASDAQ: IMCR (Immunocore Holdings plc)
Kemas kini terakhir: 3 jam lalu29.40
-0.08 (-0.27%)
| Penutupan Terdahulu | 29.48 |
| Buka | 29.53 |
| Jumlah Dagangan | 924,921 |
| Purata Dagangan (3B) | 429,860 |
| Modal Pasaran | 1,514,059,264 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.75 |
| Harga / Jualan (P/S) | 3.79 |
| Harga / Buku (P/B) | 3.87 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2026 |
| Margin Keuntungan | -6.48% |
| Margin Operasi (TTM) | -3.85% |
| EPS Cair (TTM) | -0.430 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 864.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 114.67% |
| Nisbah Semasa (MRQ) | 6.36 |
| Aliran Tunai Operasi (OCF TTM) | 31.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.36 M |
| Pulangan Atas Aset (ROA TTM) | -1.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Immunocore Holdings plc | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | 5.0 |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | 1.86 |
|
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 5.18% |
| % Dimiliki oleh Institusi | 97.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 30 Jun 2026 | 4,869,798 |
| Primecap Management Co/Ca/ | 30 Jun 2026 | 3,638,241 |
| Bellevue Group Ag | 30 Jun 2026 | 2,788,245 |
| Tang Capital Management Llc | 30 Jun 2026 | 2,649,368 |
| Caligan Partners Lp | 30 Jun 2026 | 1,381,317 |
| Kynam Capital Management, Lp | 30 Jun 2026 | 1,375,000 |
| Bvf Inc/Il | 30 Jun 2026 | 1,294,463 |
| Trails Edge Capital Partners, Lp | 30 Jun 2026 | 1,063,234 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |